ATP1B2
ENSG00000129244
Target class
Transporter
Chromosome
17
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- AMOG
- Target name
- ATP1B2
- Gene name
- ATPase Na+/K+ transporting subunit beta 2
- Gene symbol
- ATP1B2
- Protein name
- Sodium/potassium-transporting ATPase subunit beta-2 (Adhesion molecule in glia) (AMOG) (Sodium/potassium-dependent ATPase subunit beta-2)
- Gene biotype
- Protein coding
- Gene family
- ATPase Na+/K+ transporting subunits
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 51
- Highest tissue expression
- 555.88
- Tissue specificity (Gini)
- 0.743
- Tissue specificity (tau)
- 0.888
- KEGG gene identifiers
- hsa:482
- Protein interaction confidence
- 0.845577
- Protein interaction partners
- 26
- R-HSA-210991
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 7657770
- Start position
- 7646627
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Single-pass type II membrane protein.
- Tissue specificity (tau)
- 0.888239
- Expression inequality (Gini)
- 0.743187
Expression in transcripts per million
- Brain - Cerebellum
- 555.88
- Brain - Cerebellar Hemisphere
- 490.26
- Brain - Cortex
- 313.61
- Brain - Caudate (basal ganglia)
- 293.52
- Brain - Nucleus accumbens (basal ganglia)
- 254.22
Expression in transcripts per million
- Brain - Cerebellum555.88
- Brain - Cerebellar Hemisphere490.26
- Brain - Cortex313.61
- Brain - Caudate (basal ganglia)293.52
- Brain - Nucleus accumbens (basal ganglia)254.22
- Brain - Anterior cingulate cortex (BA24)252.64
- Brain - Putamen (basal ganglia)241.61
- Brain - Frontal Cortex (BA9)236.58
- Brain - Amygdala228.19
- Brain - Substantia nigra179.28
- Brain - Hypothalamus145.52
- Brain - Hippocampus124.45
- Brain - Spinal cord (cervical c-1)71.49
- Pituitary61.14
- Ovary49.84
- Nerve - Tibial30.84
- Fallopian Tube30.23
- Cervix - Endocervix30.13
- Cervix - Ectocervix22.08
- Uterus21.92
- Colon - Sigmoid14.62
- Esophagus - Gastroesophageal Junction14.04
- Adrenal Gland12.66
- Testis12.15
- Prostate11.1
And 29 more, listed on the interactive page.
- GO:0006883
- GO:0030007
- GO:0036376
- GO:0050821
- GO:0086009
- GO:0086064
- GO:1903278
- GO:1903288
- GO:1990573
- GO:0005886
- GO:0005890
- GO:0016324
- GO:0016328
- GO:0097449
- GO:0001671
- GO:0005515
- GO:0030674
- GO:0051117
- GO:0141109
decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- renal
- cardiovascular
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- renal
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac contractility
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264ventricular fibrillation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular fibrillation
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor